Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

Loomba, Rohit; Noureddin, Mazen; Kowdley, Kris V.; Kohli, Anita; Sheikh, Aasim; Neff, Guy; Bhandari, Bal Raj; Gunn, Nadege; Caldwell, Stephen H.; Goodman, Zachary; Wapinski, Ilan; Resnick, Murray; Beck, Andrew H.; Ding, Dora; Jia, Catherine; Chuang, Jen‐Chieh; Huss, Ryan S.; Chung, Chuhan; Subramanian, G. Mani; Myers, Robert P.; Patel, Keyur; Borg, Brian B.; Ghalib, Reem; Kabler, Heidi; Poulos, John; Younes, Ziad; Elkhashab, Magdy; Hassanein, Tarek; Iyer, Rajalakshmi; Ruane, Peter; Shiffman, Mitchell L.; Strasser, Simone; Wong, Vincent Wai‐Sun; Alkhouri, Naim; for the ATLAS Investigators

doi:10.1002/hep.31622

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

Background and Aims Advanced fibrosis attributable to NASH is a leading cause of end‐stage liver disease. Approach and Results In this phase 2b trial, 392 patients with bridging fibrosis or compensated cirrhosis (F3‐F4) were randomized to receive placebo, selonsertib 18 mg, cilofexor 30 mg, or fi…